Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
NCT07309211
·
clinicaltrials.gov ↗
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class
Conditions
SCLC, Limited Stage
Sponsor
The First Affiliated Hospital with Nanjing Medical University